Shares in Adocia SA (PARIS:ADOC) dropped more than 30 percent Friday, falling €12.67 (US$13.55) to close at €27.60 (US$29.51), on news that Eli Lilly and Co. was once again exiting an alliance in type 1 and type 2 diabetes. Read More
The cell surface protein CD99 is expressed on cancer stem cells in acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS), and it could serve as both a marker and a therapeutic target in those disorders. Read More
Novan Inc.'s effort to market the first-ever topical nitric oxide (NO) macromolecule – one that would be the first new chemical entity for acne in decades – stumbled on word that topical SB2014 met with success in one phase III trial but only a partial win in the second, identical study. Read More
Jounce Therapeutics Inc. rose to the head of the pack of early 2017 biopharma IPOs by pricing an upsized offering of 6.365 million shares at $16 apiece, above the intended range of $13 to $15, for proceeds of $101.8 million, up from its proposed $75 million raise. Read More
Basic developmental biology and organ transplantation both got a boost this week, with two groups reporting progress in generating chimeras, and generating medically useful cell types using those chimeras. Read More
NEW DELHI –In the wake of the death of a U.S. woman who had been infected with a drug-resistant bug in India, the country's drug regulator has ordered all companies involved in the drug supply chain system to strictly follow the country's guidelines in the Drugs and Cosmetics Act on the sale of medicines. Read More
Biscayne Neurotherapeutics Inc., of Miami, completed a $3 million series B financing. The financing was led by the Global Health Sciences Fund of Quark Venture and GF Securities, along with Mesa Verde Venture Partners. Existing Biscayne investors and new private investors also participated. Read More
Abbvie Inc., of North Chicago, posted fourth quarter 2016 net product revenues of $6.78 billion, down about 2 percent from the fourth quarter of 2015 and below analysts' average estimate of $6.91 billion, according to Thomson Reuters I/B/E/S/. Read More
Pfizer Inc., of New York, said that the EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending Xeljanz (tofacitinib citrate) 5 mg twice daily for the treatment of patients with moderate to severe active rheumatoid arthritis (RA). Read More
Foresee Pharmaceuticals Co. Ltd., of Taipei, Taiwan, reported that an open-label, single-arm phase III trial of FP-001 LMIS (leuprolide mesylate) 50 mg in patients with advanced prostate carcinoma achieved its primary efficacy endpoint in 97 percent of the study's participants. Read More
